Issue link: http://osercommunicationsgroup.uberflip.com/i/709458
C h a i n D r u g s t o r e D a i l y 5 1 Tu e s d a y, A u g u s t 9 , 2 0 1 6 SMART TEMPS TEMPERATURE MONITORING VIA WEB In the pharmaceutical industry, tempera- ture management is crucial in maintain- ing the appropriate temperature of valu- able, expensive drugs, vaccines and bio- logics. SMART Temps LLC, founded in 2004 and located in Mishawaka, Indiana, specializes in temperature monitoring solutions for increased compliance, loss prevention and patient safety. SMART Temps partners with more than 14,000 locations nationwide, providing a solu- tion exceeding CDC Guidelines on Vaccine Storage and Handling (June 2016), as well as various state require- ments and standards. This automated temperature monitoring system logs tem- peratures 24/7, removing the manual process. The wireless system alerts dur- ing any temperature excursion or power outage via text/email/phone call. The reporting tool is completely web-based, allowing real time remote access from anywhere. The SMART Temps equip- ment has the ability to communicate via ethernet, Wi-Fi or even cellular. Josh Griggs, MBA, Director of Healthcare Sales, says, "The target audi- ence for SMART Temps is pharmacy and clinical administration, along with indi- viduals who manage compliance or facility management. We are most proud of the product we pro- vide and the customer base we manage. Currently, we monitor and manage just north of 14,000 locations nationwide, including more than 6,000 retail pharmacies. We have a proven track record, with the abil- ity to implement and manage the largest to the smallest organizations. Not to mention, our in-house Customer Support Specialists are always available for ques- tions or assistance." Because SMART Temps frees its customers from a manual logging process, a huge productivity enhance- ment is provided. In addition, the alerting tool not only delivers a large ROI, which prevents inventory loss, it also facilitates the efficacy of inventory, thus ensuring that the client's inventory is never compromised. As a result, SMART Temps pharmacy cus- tomers and patients have peace of mind regarding the integrity of the medications/vaccines they receive. Griggs continues, "NACDS allows us to network with all of our current and potential partners. Our main goal is to learn more about the specific needs of our partners, which enables us to provide the solution most suitable for the specific pharmacy environment." SMART Temps offers a free 30-day trial. For more information, visit booth #2121, call 877.272.3111, x160, email josh@smart-temps.com or go to www.smart-temps.com. SATISFY CUSTOMERS BY ADDRESSING "SNACK MOMENTS" An interview with Diane Striegel, M.S., R.D.N., Senior Manager Industry Development. CDD: As people are snacking more often, how do your snack foods fit into multiple day parts? DS: Mondelēz International has invest- ed in consumer snacking research to ensure we are focused on the big snack- ing growth moments. Snacking moments happen across the day, but people snack differently and have dif- ferent drivers. We have gone beyond day parts and identified distinct Snack Moments. A "Moment" is the intersec- tion of a consumer, a need state and a consumption occasion. We grouped these occasions together based on com- mon traits to create our focus Snack Moments: Highlight Wholesome, Help Meal Skippers, No Regret Treat, Delightful Variety, Premium Experience, Easier On-The-Go and Expand Entertaining. Understanding these Snack Moments, we continue to develop and refine our snack portfolio to ensure our snacks fulfill one or more of these needs sought throughout the day. CDD: How do your snacks help elevate a grocer's grab and go offerings? DS: Time compression has driven the need for portability and increased con- venience. With increasingly busy sched- ules, active lifestyles and demanding expectations, consumers are looking for ease on the go and functional packaging to complement their snacking habits. Our Easier On-The-Go Snack Moment items deliver against the consumer need for ing our latest, Smoked Gouda, Mediterranean Olive and seasonal Limited Edition Sriracha! CDD: Many snack consumers are seeking low-guilt ways to indulge. How does your snack lineup address this need? DS: We know that many consumers are looking for light-textured sweet snacks that are delicious, but not too heavy. With that in mind we developed OREO Thins, a thin and crispy cookie that delivered on the OREO taste consumers love, but in a new, lighter-textured format. Originally launched in July 2015, OREO Thins now come in five varieties (Original, Golden, Mint, Lemon and Chocolate Creme) as well as a convenient on-the-go pack. Also, on August 1st, we introduced Chips Ahoy! Thins, thin, crispy cookies avail- able in two varieties (Chocolate Chip and Cinnamon Sugar). For more information, visit booth #2133 or call 973.503.2000. away from home portable snacks. CDD: How do your snack foods fit into modern preferences for brighter, bolder flavors and clean- er ingredient lists? DS: We have products that address the Delightful Variety and Highlight Wholesome Snack Moments. For Delightful Variety, strong flavor innova- tion has created new family favorites like Cinnamon Bun Flavored and Red Velvet Flavored OREO cookies. The OREO Wonder Vault continues to delight consumers with new and excit- ing flavors like our latest limited edition Choco Chip Flavored OREO cookies featuring a first-ever dual-flavored wafer, golden and chocolate, with chocolate chip flavored creme inside. For Highlight Wholesome, Original Triscuit is made with three simple ingre- dients (wheat, oil and salt) and can be paired with a wide variety of flavorful toppings. We are inspiring new flavor varieties for everyday Triscuit, includ- IMMUNE DESIGN'S GLAAS PLATFORM SHOWN TO MODULATE ALLERGIC IMMUNE RESPONSE Immune Design, a clinical-stage immunotherapy company focused on oncology, has announced the presenta- tion of data demonstrating the potential of its GLAAS™ platform to modify allergic immune responses present in pollen and peanut allergies. Results from these studies were highlighted at the 2016 American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Los Angeles. Immune Design presented data highlighting the ability of GLA, a syn- thetic TLR4 agonist and the core of the GLAAS platform, to modify the abnor- mal allergic immune response observed in peripheral blood from patients with pollen allergies. Specifically, the research demonstrated that GLA signif- icantly decreased the level of Th2 cytokines, IL-5 and IL-13, and increased the level of Th1 cytokines, IFNγ and IL-12, to grass pollen aller- gen in the peripheral blood mononu- clear cells from allergic donors. Th2 cytokines promote the development of an allergic inflammatory response in people with allergies. Th1 cytokines can counterbalance Th2 immune responses and potentially aid in the treatment of allergic diseases. "These presentations add to the large and growing body of data sup- porting the potential of the GLAAS platform for the treatment of chronic diseases beyond cancer, where Immune Design is focused, including allergy," said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design. "Investigational agents leveraging GLAAS in oncology are currently in clinical development in randomized Phase 2 studies in soft tissue sarcoma and Non-Hodgkin's lymphoma. Via selective external collaborations and licenses, we are expanding its develop- ment in other novel diseases such as peanut food allergy and infectious dis- eases such as respiratory syncytial virus." Immune Design's GLAAS plat- form works in vivo and is based on a small synthetic molecule called GLA, or glucopyranosyl lipid adjuvant. GLA selectively binds to the TLR4 receptor and causes potent activation of dendrit- ic cells (DCs) leading to the production of cytokines and chemokines that drive a Th1-type immune response. When GLA is accompanied by an antigen and injected into a patient, the combination is taken up by DCs and leads to the pro- duction and expansion of immune cells called CD4 T helper lymphocytes with a Th1 phenotype. These CD4 T cells play a key role in boosting pre-existing CTLs that are specific to the same anti- gen, neutralize a Th2 phenotype; and provide help to other immune cells and natural killer cells that are also impor- tant in the overall immune response. GLA can also be used to induce local and systemic immune responses against cancer by directly injecting it into tumors, where it induces a pro- inflammatory state of the tumor microenvironment. Immune Design believes that GLAAS product candi- dates have the potential to target multi- ple types of cancer, as well as infec- tious, allergic and autoimmune dis- eases. GLAAS-based product candi- dates have now been evaluated in over 1400 subjects in Phase 1 and Phase 2 trials demonstrating an acceptable safe- ty profile. About Immune Design Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight chronic diseases. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specif- ic cytotoxic T cells, while also enhanc- ing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary focus of Immune Design's ongoing immuno- oncology clinical programs, are prod- ucts of its two synergistic discovery platforms, ZVex™ and GLAAS, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.